Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Ranieri

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Clinical and Laboratory Haematology|January 1, 1984
Evaluation of the effectiveness of DDAVP in surgery and in bleeding episodes in haemophilia and von Willebrand's disease. A study on 43 patientsG Mariana, N Ciavarella, M G Mazzucconi, et al.
Blood|September 1, 1985
Hemophilia B with inhibitor: molecular analysis of the subtotal deletion of the factor IX geneH J Hassan, A Leonardi, R Guerriero, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 30, 1999
Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferationZ Yang, P Birkenhauer, F Julmy, et al.
Blood Purification|July 19, 2006
Is the efficacy of LDL apheresis in ischemic optic neuropathy linked to a reduction in endothelial activation markers?A Ramunni, G Ranieri, G Giancipoli, et al.
Tissue Engineering|August 15, 2000
eNOS-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle cell proliferation in vitroK N Kader, R Akella, N P Ziats, et al.
Blood|December 1, 1985
High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC)G Ciavarella, N Ciavarella, S Antoncecchi, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|March 1, 2000
Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutationV De Mitrio, R Marino, F A Scaraggi, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 1, 2025
Racial Health Disparity and Risk of Multiple Myeloma: Implications for Energy Balance InterventionsAmber J Normann, Rebekah L Wilson, Ellaney Matarese, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1988
Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand diseaseK Y Ngo, V T Glotz, J A Koziol, et al.
Journal of Biomedical Materials Research|June 1, 1995
Synthesis and characterization of fluoropolymeric substrata with immobilized minimal peptide sequences for cell adhesion studies. IT G Vargo, E J Bekos, Y S Kim, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Clinical and Laboratory Haematology|January 1, 1984
Evaluation of the effectiveness of DDAVP in surgery and in bleeding episodes in haemophilia and von Willebrand's disease. A study on 43 patientsG Mariana, N Ciavarella, M G Mazzucconi, et al.
Blood|September 1, 1985
Hemophilia B with inhibitor: molecular analysis of the subtotal deletion of the factor IX geneH J Hassan, A Leonardi, R Guerriero, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 30, 1999
Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferationZ Yang, P Birkenhauer, F Julmy, et al.
Blood Purification|July 19, 2006
Is the efficacy of LDL apheresis in ischemic optic neuropathy linked to a reduction in endothelial activation markers?A Ramunni, G Ranieri, G Giancipoli, et al.
Tissue Engineering|August 15, 2000
eNOS-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle cell proliferation in vitroK N Kader, R Akella, N P Ziats, et al.
Blood|December 1, 1985
High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC)G Ciavarella, N Ciavarella, S Antoncecchi, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|March 1, 2000
Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutationV De Mitrio, R Marino, F A Scaraggi, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 1, 2025
Racial Health Disparity and Risk of Multiple Myeloma: Implications for Energy Balance InterventionsAmber J Normann, Rebekah L Wilson, Ellaney Matarese, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1988
Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand diseaseK Y Ngo, V T Glotz, J A Koziol, et al.
Journal of Biomedical Materials Research|June 1, 1995
Synthesis and characterization of fluoropolymeric substrata with immobilized minimal peptide sequences for cell adhesion studies. IT G Vargo, E J Bekos, Y S Kim, et al.
Pageof 4